TCMD

Over the past six months, TCMD's stock price has been influenced by several events. Tactile Medical reported strong fourth-quarter 2025 and first-quarter 2026 financial results, with revenue increases. Management raised its full-year 2026 revenue guidance. Tactile Systems Technology closed the acquisition of LymphaTech, Inc. New Medicare prior authorization requirements for pneumatic compression devices have been noted as a potential near-term headwind. As of May 9, 2026, TCMD shares have decreased by 11.6% since the beginning of 2026, but increased by 64.20% over the past year. Insiders have sold more company stock than they have bought, with total insider sales of approximately $1.43 million.